HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A novel P2Y(12) adenosine diphosphate receptor antagonist that inhibits platelet aggregation and thrombus formation in rat and dog models.

Abstract
Irreversible platelet inhibitors, such as aspirin and clopidogrel, have limited anti-thrombotic efficacy in the clinic due to their bleeding risk. We have developed an orally active reversible P2Y(12) receptor antagonist, BX 667. The aim of this study was to determine if the reversible antagonist BX 667 had a greater therapeutic index than the irreversible P2Y(12) receptor antagonist clopidogrel. Since BX 667 is rapidly converted to its active metabolite BX 048 in rats, we first injected BX 048 intravenously (iv) in a rat arterial venous (A-V) shunt model of thrombosis. BX 048 dose- and concentration-dependently attenuated thrombosis. When administered orally, BX 667 and clopidogrel had similar efficacy, but BX 667 caused less bleeding than clopidogrel. In a rat model of a platelet-rich thrombus induced by vessel injury with FeCl(2), both BX 667 and clopidogrel exhibited higher levels of thrombus inhibition after oral administration compared to their potency in the A-V shunt model. Again, BX 667 caused less bleeding than clopidogrel. In a dog cyclic flow model, iv injection of either BX 667 or clopidogrel dose-dependently reduced thrombus formation with lower bleeding for BX 667 than clopidogrel. Inhibition of thrombosis was highly correlated with inhibition of ADP-induced platelet aggregation in these animal models. In dogs pre-treated with aspirin, BX 667 maintained its wider therapeutic index, measured by inhibition of platelet aggregation over bleeding, compared to the aspirin-clopidogrel combination. These data demonstrate that the reversible P2Y(12) receptor antagonist, BX 667, has a wider therapeutic index than clopidogrel in experimental models of thrombosis.
AuthorsYi-Xin Wang, Jon Vincelette, Valdeci da Cunha, Baby Martin-McNulty, Cornell Mallari, Richard M Fitch, Serene Alexander, Imadul Islam, Brad O Buckman, Shendong Yuan, Joseph M Post, Babu Subramanyam, Ronald Vergona, Mark E Sullivan, William P Dole, John Morser, Judi Bryant
JournalThrombosis and haemostasis (Thromb Haemost) Vol. 97 Issue 5 Pg. 847-55 (May 2007) ISSN: 0340-6245 [Print] Germany
PMID17479197 (Publication Type: Journal Article)
Chemical References
  • Membrane Proteins
  • P2ry12 protein, rat
  • Platelet Aggregation Inhibitors
  • Purinergic P2 Receptor Antagonists
  • Receptors, Purinergic P2
  • Receptors, Purinergic P2Y12
  • Clopidogrel
  • Ticlopidine
Topics
  • Animals
  • Arteriovenous Shunt, Surgical
  • Carotid Artery Injuries (drug therapy)
  • Clopidogrel
  • Disease Models, Animal
  • Dogs
  • In Vitro Techniques
  • Male
  • Membrane Proteins (antagonists & inhibitors)
  • Molecular Structure
  • Platelet Aggregation (drug effects)
  • Platelet Aggregation Inhibitors (blood, chemistry, pharmacology)
  • Purinergic P2 Receptor Antagonists
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Purinergic P2
  • Receptors, Purinergic P2Y12
  • Thrombosis (prevention & control)
  • Ticlopidine (analogs & derivatives, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: